Vivani Medical, Inc.

VANI

Healthcare|Biotechnology|US

$1.07

+0.03 (+2.88%)

Tangible Book / Share

$0.22

Cash / Share

$0.23

Analyst Consensus

Buy2 analysts

Strong Buy

Buy

Hold

Sell

Strong Sell

Consensus Target

$4.00

Implied Upside

+273.8%

Low Target

$4.00

High Target

$4.00

Price Target Trend

Last Month

—

0 targets

Last Quarter

—

0 targets

Last Year

$4.00

1 target · +274% vs price

All Time

$4.00

1 target · +274% vs price

Rating Trend

Dec 25

3 buy · 0 hold · 0 sell

Jan 26

3 buy · 0 hold · 0 sell

Feb 26

3 buy · 0 hold · 0 sell

Mar 26

3 buy · 0 hold · 0 sell

Apr 26

3 buy · 0 hold · 0 sell

May 26

3 buy · 0 hold · 0 sell

Jun 26

3 buy · 0 hold · 0 sell

Jul 26

3 buy · 0 hold · 0 sell

Aug 26

3 buy · 0 hold · 0 sell

Sep 26

3 buy · 0 hold · 0 sell

Oct 26

3 buy · 0 hold · 0 sell

Nov 26

3 buy · 0 hold · 0 sell

Recent Price Targets

Date	Firm	Analyst	Target	Price Then	Source
Jun 23, 2026	Lake Street		$4.00(+239%)	$1.18	TheFly

Recent Rating Actions

Firm	Action	Rating	Date
HC Wainwright & Co.	maintain	Buy	Mar 31, 2026
HC Wainwright & Co.	maintain	Buy	Sep 2, 2025
HC Wainwright & Co.	maintain	Buy	May 19, 2025
HC Wainwright & Co.	maintain	Buy	Apr 16, 2025
HC Wainwright & Co.	maintain	Buy	Apr 4, 2025
HC Wainwright & Co.	maintain	Buy	Mar 26, 2025
HC Wainwright & Co.	maintain	Buy	Mar 13, 2025
ThinkEquity	maintain	Buy	Dec 5, 2022

Earnings History

Next report: Nov 12, 2026 · EPS est. $-0.07

Report Date	EPS Actual	EPS Est.	Revenue Actual	Revenue Est.
Aug 13, 2026	$-0.07	$-0.08	—	—
May 13, 2026	$-0.08	$-0.08	—	—
Mar 26, 2026	$-0.09	$-0.09	—	—
Nov 13, 2025	$-0.11	$-0.12	—	—
Aug 13, 2025	$-0.12	$-0.10	—	—
May 13, 2025	$-0.11	$-0.10	—	—
Mar 31, 2025	$-0.11	$-0.10	$398.0K	—
Nov 13, 2024	$-0.11	$-0.11	—	—

News

Vivani Medical Announces Participation in Upcoming Investor Conferences

ALAMEDA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants utilizing its proprietary NanoPortal™ technology, today announced its planned participation in two upcoming investor conferences:

Sep 3, 2026globenewswire.com

Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merger into Cortigent Holdings and initiation of trading on the Nasdaq exchange under ticker symbol CRGT an…

Aug 13, 2026globenewswire.com